TGFB1 and chronic obstructive pulmonary disease: In contrast to other studies that focus primarily on the local effects of TGF-β in the lung, our study’s strength lies in its exploration of systemic biomarkers, providing evidence that U-II and TGF-β may not only act locally, but also serve as systemic indicators of fibrotic activity in COPD.